A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04660799 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: Rituximab IV
DRUG: Rituximab SC
DRUG: Rituximab IV
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Paracetamol
DRUG: Diphenhydramine hydrochloride or alternative antihistamine

Sponsor

Hoffmann-La Roche